The Role of TBX3 in Human ES Cell Differentiation
NCT00581152 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2021-01-25
Summary
Stem cells can develop into every cell, every tissue and every organ in the human body, e.g., they can make any kind of cells in the human body. Stem cells reproduce themselves many times over and over. Their almost limitless potential has made stem cells a significant focus of medical research. But before scientists can use stem cells for medical purposes, they must first learn how to harness their power. They cannot treat disease until they learn how to manipulate stem cells to get them to develop into specific tissues or organs.
We know that turning genes on and off is crucial to the process differentiation, so we can add some factor into the culture dish and observe stem cells to differentiate into specific types of cells. But some sort of signal is needed to actually trigger the stem cells to differentiate. We are still searching for that signal. If we can ultimately learn how to direct stem cells to differentiate into one type of tissue or another, then we can use them to treat patients. In this proposal, we will first examine this step.
We propose a novel approach to understanding differentiation of human embryo stem (hES) cells, by studying TBX3, a protein called a transcription factor that controls the expression of other genes. In humans, the loss of function of TBX3 causes Ulnar-Mammary Syndrome, a genetic disorder that can pass from one generation to the next. Furthermore, our preliminary results show that TBX3 is downstream mediator of another protein, BMP4. BMP4 is a known key regulator for hES cell differentiation. Thus, TBX3 is an attractive candidate as a downstream mediator of BMP4 in hES cell differentiation. We will test TBX3 effects on hES cell differentiation if down-regulate TBX3 in hES cells with a technology called siRNA knockdown. We will identify the genes controlled by TBX3 with a recently invented powerful technology called CHIP-GLAS. This technique allows us to examine thousands of genes on a small chip in a single experiment. We expect that the innovative experiments proposed here will open a new avenue to understanding the signal of hES cell differentiation.
Conditions
- TBX3
- Cell Differentiation
Sponsors & Collaborators
-
CIRM SEED Grant
collaborator UNKNOWN -
University of California, Irvine
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-08-31
- Primary Completion
- 2010-08-28
- Completion
- 2010-08-28
More Related Trials
-
TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
NCT02065362 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers
NCT03134027 ·Status: TERMINATED
-
Development of a Cell Culture Process for the Production of Human T-lymphocyte Precursors
NCT05118113 ·Status: UNKNOWN ·Phase: NA
-
Safety Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection
NCT01914263 ·Status: UNKNOWN ·Phase: PHASE1
-
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
NCT00923390 ·Status: TERMINATED ·Phase: PHASE1
-
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
NCT04815356 ·Status: RECRUITING ·Phase: PHASE1
-
T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
NCT06783270 ·Status: RECRUITING ·Phase: PHASE1
-
Functional Plasticity of Human IL-17-producing CD8+ T Cells
NCT03291639 ·Status: COMPLETED
-
A Long Term Follow-up Study of TScan TCR-T Products
NCT06976736 ·Status: RECRUITING
-
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
NCT05035407 ·Status: TERMINATED ·Phase: PHASE1
-
Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
NCT05349890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine
NCT04672473 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy
NCT01339000 ·Status: TERMINATED ·Phase: PHASE2
-
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma
NCT03354390 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors
NCT00576537 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation
NCT00405327 ·Status: COMPLETED ·Phase: PHASE2
-
Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy
NCT00889954 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
NCT05321940 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
NCT02318394 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
NCT03515252 ·Status: COMPLETED ·Phase: PHASE1
-
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
NCT01567891 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma
NCT01240005 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines
NCT01153113 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
NCT05620342 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides
NCT01645293 ·Status: UNKNOWN ·Phase: PHASE1